ECOR

ElectroCore Inc

electroCore, Inc. (NASDAQ:ECOR - Get Free Report) Director Daniel Goldberger sold 16,072 shares of the firm's stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $6.02, for a total transaction of $96,753.44. Following the sale, the director owned...

electroCore (ECOR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Relay Therapeutics (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

electroCore, Inc. (NASDAQ:ECOR - Free Report) - Equities researchers at HC Wainwright lifted their FY2030 earnings per share estimates for shares of electroCore in a research note issued to investors on Friday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...

electroCore (NASDAQ:ECOR - Get Free Report) issued its earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.01. The firm had revenue of $9.24 million for the quarter, compared to analyst estimates of $9.09...

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

electroCore (NASDAQ:ECOR) executives highlighted record fourth-quarter revenue growth, expanding adoption within the U.S. Department of Veterans Affairs (VA) system, and accelerating sales of its Truvaga wellness product during the company's fourth-quarter and full-year 2025 earnings call. Managemen...

electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?